11/12/2025
*Transparency, Policy, and Patient Impact*
At AdAstra BIO, we’re dedicated to ensuring that life science innovation and policy work hand in hand to strengthen patient access and ecosystem sustainability.
This week, patient advocates and policy leaders at the BIO Patient Advocacy Changemaker Event (PACE) called for greater transparency in the Drug Pricing Program emphasizing that its original intent was to help patients in need, not expand provider profits.
“The intention was really for the savings to help safety net hospitals bolster access and further serve vulnerable patients,” shared Anna Hyde of the Arthritis Foundation.
“Transparency seems to be where the oxygen is right now,” added Brian Connell of Blood Cancer United.
As BIO noted:
“Regulators and policymakers must reassess whether the program is meeting not just its original intent, but the broader needs of Americans.”
At AdAstra BIO, we believe that advocacy begins with accountability and that programs like 340B must evolve with clarity, data, and community collaboration to truly serve patients.
📰 Read the full article on https://ow.ly/uTiV50XqAFT: https://ow.ly/TauX50XqAFU
Photo from https://www.mhalink.org/340b/